myellama therapeutics
Updated: February 09, 2026
Founders: Brent Zanke, Alissa Visram
Country: Canada | Add Funding
Website: https://myellama.com/
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
Website: https://myellama.com/
Myellama Therapeutics is a preclinical company developing a family of proprietary cellular and multispecific nanoantibodies for the treatment of myeloma. These antibodies, TACI/BCMA, are naturally found in camelids such as llamas. They effectively target T cells or natural killer cells to malignant plasma cells. They recognize the TACI marker on the surface of myeloma cells, rather than the more common BCMA marker. Now, patients requiring additional treatment before or after existing immunotherapy drugs, such as ciltacebtagene autoleucel, idecabtagene vicleucel, teclistimab, or elranatamab, will have more options. The company is getting ready for simultaneous Health Canada CTA and FDA NDA application with first patient enrollement anticipated in 2027
